Analysis of drug-induced effect patterns to link structure and side effects of medicines

The high failure rate of experimental medicines in clinical trials accentuates inefficiencies of current drug discovery processes caused by a lack of tools for translating the information exchange between protein and organ system networks. Recently, we reported that biological activity spectra (biospectra), derived from in vitro protein binding assays, provide a mechanism for assessing a molecule's capacity to modulate the function of protein-network components. Herein we describe the translation of adverse effect data derived from 1,045 prescription drug labels into effect spectra and show their utility for diagnosing drug-induced effects of medicines. In addition, notwithstanding the limitation imposed by the quality of drug label information, we show that biospectrum analysis, in concert with effect spectrum analysis, provides an alignment between preclinical and clinical drug-induced effects. The identification of this alignment provides a mechanism for forecasting clinical effect profiles of medicines.

[1]  N. L. Johnson,et al.  Multivariate Analysis , 1958, Nature.

[2]  J. H. Ward.  Hierarchical Grouping to Optimize an Objective Function , 1963 .

[3]  L. W. Hamilton,et al.  Sex differences in response to taste and postingestive consequences of sugar solutions , 1976, Physiology & Behavior.

[4]  Turan M. Itil,et al.  The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG) , 1983, Progress in Neurobiology.

[5]  Somatic symptoms in depression and antidepressants. , 1983, The Journal of clinical psychiatry.

[6]  Allan R. Wilks,et al.  The new S language: a programming environment for data analysis and graphics , 1988 .

[7]  J N Weinstein,et al.  Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.

[8]  P. Labute,et al.  Binary Quantitative Structure—Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands. , 1999 .

[9]  I. Hindmarch.  Myths, medicine and the media , 1999 .

[10]  E. J. German,et al.  Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? , 1999, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[11]  S. Steiner,et al.  Expression profiling in toxicology--potentials and limitations. , 2000, Toxicology letters.

[12]  G. Rubanyi,et al.  Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints* , 2000, The Journal of Biological Chemistry.

[13]  B. Antkowiak.  How do general anaesthetics work? , 2001, Naturwissenschaften.

[14]  Lee Bennett,et al.  Prediction of compound signature using high density gene expression profiling. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[16]  Paul Labute,et al.  A probabilistic approach to high throughput drug discovery. , 2002, Combinatorial chemistry & high throughput screening.

[17]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[18]  J. Rockett.  Use of genomic data in risk assessment , 2002, Genome Biology.

[19]  Ricard V. Solé,et al.  A Model of Large-Scale proteome Evolution , 2002, Adv. Complex Syst..

[20]  T. Zacharewski,et al.  Workshop overview: use of genomic data in risk assessment. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  W. Dimpfel.  Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG). , 2003, European journal of medical research.

[22]  D. Goldstein,et al.  Pharmacogenetics [7] (multiple letters) , 2003 .

[23]  M. Tyers,et al.  From genomics to proteomics , 2003, Nature.

[24]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[25]  M. Pellegrini.  Defining interacting partners for drug discovery , 2003, Expert opinion on therapeutic targets.

[26]  D. Sanger.  The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents , 2004, CNS Drugs.

[27]  Dan M. Bolser,et al.  Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map) , 2005, Bioinform..

[28]  A. Fliri,et al.  Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.

[29]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.